Is TB-500 Legal in Wisconsin? How to Access It Legally
See the public record for TB-500
At a glance
- Federal approval / No FDA-approved TB-500 product; none approved in the EU, UK, Canada, Australia or several other countries FDA checked [1]
- FDA lists / In none of the three categories on the list for state-licensed pharmacies and physicians, and absent from the outsourcing-facility list [2][3][4]
- Safety-risk page / Sits in the nominated-but-withdrawn table; removal from category 2 was not a safety finding [8]
- Advisory vote / FDA's Pharmacy Compounding Advisory Committee voted on 23 July 2026 to recommend adding it, against staff advice; non-binding [9][6]
- HHS draft / Conditional enforcement discretion for TB-500 acetate injections, with a patient-specific prescription required [6][7]
- Wisconsin / Pharmacy licensure is governed by Chapter 450 [5]
- Sport / WADA prohibits thymosin-beta-4 and its derivatives, naming TB-500, at all times [10][11]
Is TB-500 legal in Wisconsin?
There is no FDA-approved TB-500, and it is in none of the categories on FDA's list for state-licensed pharmacies and physicians or on the outsourcing-facility list [1][2][3][4]. A licensed Wisconsin pharmacy therefore has no listed route to compound it. Wisconsin pharmacy licensure is governed by Chapter 450 [5].
The draft HHS policy describes conditional enforcement discretion for TB-500 acetate injections compounded by a state-licensed pharmacy or licensed physician. It does not make TB-500 an approved drug, and it creates no right to obtain the product [6][7].
The compounding rule that decides access
A state-licensed pharmacy may compound with a bulk substance only if it meets a USP or NF monograph, is a component of an FDA-approved drug, or appears on FDA's bulks list [4]. FDA found no USP or NF monograph and no FDA-approved drug containing TB-500, and it is not on the bulks list [1][4]. FDA's safety-risk page places TB-500 in the table of substances previously in category 2 whose nominators withdrew them. Removal from category 2 was not a finding that it is safe [8]. Outsourcing facilities work from a separate list, and TB-500 is not on it [3].
The July 2026 vote and the HHS draft
FDA staff proposed in July 2026 that neither TB-500 free base nor TB-500 acetate be added to the pharmacy bulks list. They cited inconsistent naming, missing impurity and endotoxin data, no evidence of effectiveness for wound healing, no human data, immunogenicity risk, and existing approved wound treatments [1]. The Pharmacy Compounding Advisory Committee voted on 23 July 2026 in favor of adding it, against the staff recommendation. That vote is advice only, and adding a substance takes formal rulemaking [9][6].
HHS's draft policy (Federal Register document 2026-22192, filed 28 October 2026, with publication scheduled for 30 October and comments due two weeks after) names TB-500 among six peptides. It covers TB-500 acetate by subcutaneous or intramuscular injection. Its conditions include a single active ingredient, a patient-specific prescription, an FDA-registered manufacturer with a certificate of analysis, and the label "This is a compounded drug product. Not for resale." [6][7]. The notice says it does not establish rights for any person, is not binding on HHS or the public, and may be revisited, for example if a safety signal or product quality issue arises [6]. Compounded drugs are not FDA-approved, and FDA does not review their safety, effectiveness or quality before marketing [6].
Buying it online, and the sport rule
TB-500 is sold online as a research-use-only injectable powder in 2 mg to 15 mg vials, alone or blended with BPC-157. A veterinary preparation appeared in 2011, marketed to boost performance in horses and greyhounds [1]. FDA found no pharmacy marketing a compounded TB-500 product and no outsourcing facility reporting one [1].
WADA names "Thymosin-beta4 and its derivatives e.g. TB-500" under S2.3. It is prohibited at all times, in and out of competition, on both the 2026 and 2027 lists [10][11].
What is known about safety
FDA found no article in which TB-500 was given to a person, no human pharmacokinetic data, and no approved dose [1]. Its stated concern for injectable TB-500 is immunogenicity, possibly amplified by aggregation and impurities, and it found no nonclinical toxicity studies [1]. An in-vitro scratch-wound test found that TB-500 at 50 microgram/mL did not induce wound closure in fibroblast cultures [1]. FDA's BPC-157 review describes a 40-year-old woman who injected a research-purpose BPC-157 plus TB-500 product (5 mg/5 mg) twice daily. She developed widespread skin hyperpigmentation and gum darkening within a week, and it recurred when she retried the product two weeks later. With two peptides in the product, FDA said it could not tell whether either caused it [12].
Frequently asked questions
Is TB-500 legal in Wisconsin?
Did the July 2026 FDA committee vote make TB-500 legal?
Does the HHS draft peptide policy authorize TB-500?
Is TB-500 banned in sport?
References
Show all 12 referencesHide references
- U.S. Food and Drug Administration.
- U.S. Food and Drug Administration.
- U.S. Food and Drug Administration.
- Bulk Drug Substances Used in Compounding of the FD&C Act | FDA.
- Wisconsin Legislature: Chapter 450.
- Official web page.
- Official web page.
- Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks | FDA.
- U.S. Food and Drug Administration.
- World Anti-Doping Agency.
- World Anti-Doping Agency.
- U.S. Food and Drug Administration.